scispace - formally typeset
Journal ArticleDOI

Pachychoroid pigment epitheliopathy.

Reads0
Chats0
TLDR
Pachychoroid pigment epitheliopathy should be suspected in eyes with a characteristic fundus appearance related to choroidal thickening and associated retinal pigment epithelial abnormalities but no history of subretinal fluid, and it should be recognised in patients frequently misdiagnosed to avoid unnecessary diagnostic testing and interventions.
Abstract
Purpose:To report nine cases of pachychoroid pigment epitheliopathy.Methods:An observational case series of nine patients who underwent comprehensive ophthalmic examination, fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, and enhanced depth imaging optical

read more

Citations
More filters
Journal Article

Enhanced Depth Imaging Optical Coherence Tomography of the Choroid in Normal Eyes

TL;DR: In this paper, the authors measured the macular choroid thickness in normal eyes at different points using enhanced depth imaging (EDI) optical coherence tomography (OCT) and evaluated the association of choroidal thickness and age.
Journal ArticleDOI

Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis.

TL;DR: The aim of this review is to recapitulate the clinical understanding of CSCR, with an emphasis on the most recent findings on epidemiology, risk factors, clinical and imaging diagnosis, and treatments options, and the novel mineralocorticoid pathway hypothesis.
Journal ArticleDOI

En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography.

TL;DR: Although clinical manifestations of pachychoroid spectrum disorders vary considerably, these entities share morphologic findings in the choroid, including increased thickness and dilated outer choroidal vessels, which localizes these changes to disease foci and shows additional findings that may unify the understanding of disease pathogenesis.
Journal ArticleDOI

Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians.

TL;DR: Current clinical trials of intravitreal anti-VEGF therapy and photodynamic therapy will provide clearer perspectives of evidence-based management of PCV and may lead to paradigm shifts in therapeutic strategies away from those currently employed in the treatment of CNV-AMD.
Journal ArticleDOI

Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management.

TL;DR: 2 large, multicenter randomized clinical trials evaluating the safety and efficacy of anti-VEGF monotherapy and combination with photodynamic therapy (PDT) recently reported initial first-year outcomes, providing level I evidence to guide clinicians in choosing the most appropriate therapy for PCV.
References
More filters
Journal ArticleDOI

A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes.

TL;DR: The decrease in the thickness of the choroid may play a role in the pathophysiologic features of various age-related ocular conditions and seems to vary topographically within the posterior pole.
Journal Article

Enhanced Depth Imaging Optical Coherence Tomography of the Choroid in Normal Eyes

TL;DR: In this paper, the authors measured the macular choroid thickness in normal eyes at different points using enhanced depth imaging (EDI) optical coherence tomography (OCT) and evaluated the association of choroidal thickness and age.
Journal ArticleDOI

Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy.

TL;DR: Enhanced depth imaging spectral-domain optical coherence tomography demonstrated a very thick choroid in patients with central serous chorioretinopathy, providing additional evidence that central serously choroidal vascular hyperpermeability may be caused by increased hydrostatic pressure in the choroids.
Journal ArticleDOI

Central serous chorioretinopathy

TL;DR: The value of treatment depends upon proper selection of cases that will not resolve without therapy, and patients with chronic CSC who receive glucocorticoid treatment for systemic disease can often be managed without having to discontinue this medication.
Related Papers (5)